13022AST
Astec® CHIROBIOTIC® R Chiral (5 μm) HPLC Columns
L × I.D. 10 cm × 4.6 mm, HPLC Column
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
10 cm × 4.6 mm
Particle size:
5 μm
Matrix active group:
ristocetin A glycopeptide phase
Pore size:
100 Å
Matrix:
high-purity silica gel particle platform, fully porous particle
Product Name
Astec® CHIROBIOTIC® R Chiral HPLC Column, 5 μm particle size, L × I.D. 10 cm × 4.6 mm
material
stainless steel column
Quality Level
description
HPLC column
product line
Astec®
packaging
pkg of 1 ea
manufacturer/tradename
Astec®
parameter
0-45 °C temperature, 241 bar pressure (3500 psi)
technique(s)
HPLC: suitable, LC/MS: suitable
L × I.D.
10 cm × 4.6 mm
matrix
high-purity silica gel particle platform, fully porous particle
matrix active group
ristocetin A glycopeptide phase
particle size
5 μm
pore size
100 Å
operating pH range
3.5-6.8
separation technique
chiral
General description
CHIROBIOTIC® R, based on the ristocetin A glycopeptide covalently bonded to high purity silica particles, has shown particular applicability to enantiomers of anionic compounds. Selectivity on CHIROBIOTIC® R strongly correlates to the organic modifier, favoring the alcohol-type mobile phases by a large margin.
CHIROBIOTIC FAQs
CHIROBIOTIC Reference Bibliography
Chiral Product Literature
- Bonded phase: Ristocetin A
- Operating pH range: 3.5 - 6.8
- Particle diameter: 5, 10 or 16 μm
- Pore size: 100 Å
CHIROBIOTIC FAQs
CHIROBIOTIC Reference Bibliography
Chiral Product Literature
Legal Information
Astec is a registered trademark of Merck KGaA, Darmstadt, Germany
CHIROBIOTIC is a registered trademark of Sigma-Aldrich Co. LLC
Still not finding the right product?
Explore all of our products under Astec® CHIROBIOTIC® R Chiral HPLC Column
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Protocols
We describe here a rapid and sensitive method to separate and measure D-2-OHG and L-2-OHG enantiomers using high-resolution mass spectrometry (HRMS) detection.
Enzyme-catalyzed synthesis of (R)- and (S)-3-hydroxy-3-(10-alkyl-10H-phenothiazin-3-yl)propanoic acids
Brem, Jurgen, et al.
Tetrahedron Asymmetry, 21 (3), 365-373 (2010)
H Henry et al.
Biomedical chromatography : BMC, 26(4), 425-428 (2011-08-16)
D-lactic acid in urine originates mainly from bacterial production in the intestinal tract. Increased D-lactate excretion as observed in patients affected by short bowel syndrome or necrotizing enterocolitis reflects D-lactic overproduction. Therefore, there is a need for a reliable and
B DeCruze et al.
Clinical oncology (Royal College of Radiologists (Great Britain)), 11(4), 252-254 (1999-09-04)
Poor prognosis (poorly differentiated and/or deep myometrial invasion) Stage I endometrial cancer can have a relapse rate as high as 50%. Traditionally, most clinical oncologists treat these patients with external beam radiotherapy after surgery but there is no evidence to
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 13022AST | 04061833513903 |